TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31898758

Group type: EXPERIMENTAL
Intervention: EMG biofeedback therapy applied to tibialis anterior muscles, 5 days a week for 3 weeks in addition to conventional physiotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional physiotherapy applications
Number of subjects: 40
Study: 30956111

Group type: EXPERIMENTAL
Intervention: Mass drug administration of ivermectin (200 μg/kg) and azithromycin (20 mg/kg)
Number of subjects: 26188

Group type: EXPERIMENTAL
Intervention: Mass drug administration of ivermectin and azithromycin
Number of subjects: 26188
Study: 27858150

Group type: EXPERIMENTAL
Intervention: 3 cups of study coffee
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 5 cups of study coffee
Number of subjects: 160

Group type: COMPARATOR
Intervention: Water (placebo)
Number of subjects: 160
Study: 27840352

Group type: EXPERIMENTAL
Intervention: Pipemidic acid (400 mg bid)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Phenazopyridine (200 mg tid)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sodium diclofenac (50 mg bid)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 80
Study: 24915914

Group type: EXPERIMENTAL
Intervention: HHHFNC
Number of subjects: 255

Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 255
Study: 23211845

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 8844

Group type: EXPERIMENTAL
Intervention: CT Colonography
Number of subjects: 8844
Study: 20553804

Group type: EXPERIMENTAL
Intervention: Active 15Hz tACS with a current density of 0.80A/m(2) for 20 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tACS
Number of subjects: 0
Study: 18285478

Group type: EXPERIMENTAL
Intervention: Amprenavir (600 mg BID)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Lopinavir (400 mg BID) plus ritonavir (100 or 200 mg BID)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combination therapy of amprenavir and lopinavir
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Amprenavir and lopinavir concentrations
Number of subjects: 37
Study: 15811048

Group type: EXPERIMENTAL
Intervention: Essential oil mouth rinse containing 0.09% zinc chloride (Tartar Control Listerine Antiseptic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control rinse
Number of subjects: 0
Study: 12761806

Group type: EXPERIMENTAL
Intervention: Once-daily controlled-release formulation of divalproex sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial enteric tablet dosed twice-daily
Number of subjects: 0
Study: 10227321

Group type: EXPERIMENTAL
Intervention: Full intervention (household and office-based patient educational materials, clinician education, practice-profiling, academic detailing)
Number of subjects: 2027

Group type: COMPARATOR
Intervention: Limited intervention (only office-based educational materials)
Number of subjects: 2027

Group type: COMPARATOR
Intervention: Control sites (usual care)
Number of subjects: 2027

Group type: EXPERIMENTAL
Intervention: Full intervention
Number of subjects: 2027

Group type: COMPARATOR
Intervention: All sites
Number of subjects: 2027
Study: 9118303

Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg orally twice a day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 1714950

Group type: EXPERIMENTAL
Intervention: MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) alternating with ABVD (doxorubicin, vinblastine, bleomycin, and dacarbazine) followed by low-dose radiotherapy (RT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: MOPP alternating with ABVD followed by low-dose RT
Number of subjects: 62
Study: 6223528

Group type: EXPERIMENTAL
Intervention: Clindamycin plus gentamicin
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 113
Study: 31287897

Group type: EXPERIMENTAL
Intervention: Tunneled version of the intervention
Number of subjects: 286

Group type: COMPARATOR
Intervention: Free-roam version of the intervention
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Both tunneled and free-roam interventions
Number of subjects: 286
Study: 28423301

Group type: EXPERIMENTAL
Intervention: Risankizumab (90 mg and 180 mg doses at weeks 0, 4, and 16)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Ustekinumab (45 or 90 mg doses at weeks 0, 4, and 16)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Risankizumab (18 mg, 90 mg, and 180 mg doses)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Ustekinumab (45 or 90 mg doses)
Number of subjects: 166
Study: 24214970

Group type: EXPERIMENTAL
Intervention: High EPA supplementation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High DHA supplementation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Linoleic acid (control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Increased erythrocyte EPA + DHA
Number of subjects: 90
Study: 24084323

Group type: EXPERIMENTAL
Intervention: Open insertion with omentum folding (OIOF group)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Regular open insertion (ROI group)
Number of subjects: 67
Study: 21114607

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg once daily
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily
Number of subjects: 929

Group type: COMPARATOR
Intervention: Glimepiride 4 mg once daily
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 929

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 929
Study: 20396719

Group type: EXPERIMENTAL
Intervention: Artrofoon treatment for 2 years
Number of subjects: 0
Study: 17126719

Group type: EXPERIMENTAL
Intervention: Ancrod
Number of subjects: 1222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1222
Study: 14970135

Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine-filled ETT cuff with water-soluble gel lubrication (Group G)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Alkalinized lidocaine-filled ETT cuff with water lubrication (Group W)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Air-filled cuff with water lubrication (Group C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine-filled cuffs (Group G and W)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Air-filled cuffs (Group C)
Number of subjects: 20
Study: 11335782

Group type: EXPERIMENTAL
Intervention: 16-item version of the Questionnaire for Identifying Children With Chronic Conditions (QuICCC-R)
Number of subjects: 1182

Group type: COMPARATOR
Intervention: 39-item version of the Questionnaire for Identifying Children With Chronic Conditions (QuICCC)
Number of subjects: 1182
Study: 9143860

Group type: EXPERIMENTAL
Intervention: 15 mg mibefradil in 15 min followed by 25 mg in 60 min (group 1)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 35 mg mibefradil in 15 min followed by 45 mg in 60 min (group 2)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 8182635

Group type: EXPERIMENTAL
Intervention: Supervised group physical therapy (3 hours weekly)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Unsupervised daily individualized exercises at home (9 months)
Number of subjects: 144
Study: 2451712

Group type: EXPERIMENTAL
Intervention: Combined modality therapy (CMT)
Number of subjects: 184

Group type: COMPARATOR
Intervention: MVVPP
Number of subjects: 184

Group type: COMPARATOR
Intervention: MOPP-ABVD
Number of subjects: 184
Study: 31326956

Group type: EXPERIMENTAL
Intervention: Flavoured tobacco
Number of subjects: 144

Group type: COMPARATOR
Intervention: Unflavoured tobacco
Number of subjects: 144
Study: 30961592

Group type: EXPERIMENTAL
Intervention: Cereal breakfast
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Egg and ham breakfast
Number of subjects: 24
Study: 27761661

Group type: EXPERIMENTAL
Intervention: Short-axis out-of-plane (SA-OOP) technique
Number of subjects: 150

Group type: COMPARATOR
Intervention: Long-axis in-plane (LA-IP) technique
Number of subjects: 150
Study: 25872667

Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (acupoints: triple energizer 5, 'Wai‐guan' and large intestine 11, 'Qu‐chi')
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 12
Study: 23104965

Group type: EXPERIMENTAL
Intervention: Parents Plus Children's Programme (PPCP)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study: 21660907

Group type: EXPERIMENTAL
Intervention: Transnasal small-caliber esophagogastroduodenoscopy (TNSC-EGD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Peroral conventional esophagogastroduodenoscopy (POC-EGD)
Number of subjects: 100
Study: 17615567

Group type: EXPERIMENTAL
Intervention: Celecoxib for 21 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo for 21 days
Number of subjects: 11
Study: 16848777

Group type: EXPERIMENTAL
Intervention: Elevated ACA velocity (> or =170 cm/s)
Number of subjects: 1975

Group type: COMPARATOR
Intervention: Normal ACA velocity
Number of subjects: 1975

Group type: EXPERIMENTAL
Intervention: Elevated ACA velocity in subjects with normal ICA/MCA velocity
Number of subjects: 1975

Group type: EXPERIMENTAL
Intervention: Elevated ACA velocity in high-risk subjects (abnormal ICA/MCA findings)
Number of subjects: 1975
Study: 15354698

Group type: EXPERIMENTAL
Intervention: Self-novelty manipulation (high self-focus condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions (neutral topics or no writing)
Number of subjects: 0
Study: 11422727

Group type: EXPERIMENTAL
Intervention: 100 mg fluvoxamine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fluvoxamine treatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fluvoxamine and paroxetine treatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Acute discontinuation
Number of subjects: 14
Study: 9827848

Group type: EXPERIMENTAL
Intervention: GLP‐1 [7‐36 amide]
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP‐1 [7‐37]
Number of subjects: 8
Study: 8129449

Group type: EXPERIMENTAL
Intervention: Continuous oral flucloxacillin 250 mg/day (group P, n = 18)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Episodic antimicrobials as clinically indicated (group E, n = 20)
Number of subjects: 38
Study: 2808961

Group type: EXPERIMENTAL
Intervention: Self-care information intervention (one page of general information and a booklet)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Self-care information intervention
Number of subjects: 391

Group type: COMPARATOR
Intervention: Control group (survey instrument only)
Number of subjects: 391
Study: 15811704

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31037288

Group type: EXPERIMENTAL
Intervention: Lapatinib plus trastuzumab
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Neoadjuvant trastuzumab and pertuzumab
Number of subjects: 422

Group type: COMPARATOR
Intervention: Lapatinib alone
Number of subjects: 422
Study: 30883336

Group type: EXPERIMENTAL
Intervention: miR‐337‐3p mimic
Number of subjects: 5

Group type: COMPARATOR
Intervention: Rap1A
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: miR‐337‐3p mimic + Rap1A
Number of subjects: 5

Group type: COMPARATOR
Intervention: Mock
Number of subjects: 5
Study: 28158243

Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Aerobic training
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 42
Study: 25156424

Group type: EXPERIMENTAL
Intervention: Dried California Mission figs (120 g/d)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Usual diet (control)
Number of subjects: 88
Study: 23681294

Group type: EXPERIMENTAL
Intervention: 9-repeat carriers of the DAT1 gene
Number of subjects: 100

Group type: COMPARATOR
Intervention: 10/10 homozygotes of the DAT1 gene
Number of subjects: 100

Group type: COMPARATOR
Intervention: DBH5'-ins/del polymorphism
Number of subjects: 100
Study: 21442809

Group type: EXPERIMENTAL
Intervention: Acupuncture at Zhongzhu (TE 3) and Waiguan (TE 5)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine medicine, physical therapy, occupational therapy, and other rehabilitation trainings
Number of subjects: 60
Study: 19845037

Group type: EXPERIMENTAL
Intervention: Metformin (arm A; n = 59)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo (arm B; n = 64)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Metformin (arm A)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo (arm B)
Number of subjects: 123
Study: 16762759

Group type: EXPERIMENTAL
Intervention: Hypertrophic cardiomyopathy (HC) patients
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 26
Study: 15205238

Group type: EXPERIMENTAL
Intervention: Mydriasis
Number of subjects: 398

Group type: COMPARATOR
Intervention: Undilated single field photography
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Dilated single field photography
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Dilated three field photography
Number of subjects: 398
Study: 11742271

Group type: EXPERIMENTAL
Intervention: LEV 0.31 mg
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: LEV 0.63 mg
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: RAC 1.25 mg
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: RAC 2.5 mg
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: All active treatments
Number of subjects: 338
Study: 9241391

Group type: EXPERIMENTAL
Intervention: Specialized AIDS education
Number of subjects: 300

Group type: COMPARATOR
Intervention: Traditional AIDS education
Number of subjects: 300
Study: 8359579

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicilate (450 mg i.v.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isotonic saline (0.9% NaCl)
Number of subjects: 8
Study: 31776029

Group type: EXPERIMENTAL
Intervention: Tdap
Number of subjects: 687

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 687
Study: 29169057

Group type: EXPERIMENTAL
Intervention: Lay health workers (LHWs) providing instrumental, informational, emotional, and appraisal support.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic social support (SSS) provided by LHWs.
Number of subjects: 0
Study: 28239036

Group type: EXPERIMENTAL
Intervention: Subcutaneous fondaparinux
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oral edoxaban
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study: 26137702

Group type: EXPERIMENTAL
Intervention: Xiaoaiping injection (60 mL, i.v., qd)
Number of subjects: 66
Study: 23032922

Group type: EXPERIMENTAL
Intervention: C-MAC D-Blade (DB)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: GlideScope (GS)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Direct Macintosh laryngoscopy (DL)
Number of subjects: 96
Study: 21114342

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 403

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 403
Study: 18242128

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2548

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2548
Study: 16357551

Group type: EXPERIMENTAL
Intervention: Physical therapy supplemented with partial weight‐bearing gait training twice weekly
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard physical therapy
Number of subjects: 38
Study: 12708605

Group type: EXPERIMENTAL
Intervention: Cinnarizine 20 mg and dimenhydrinate 40 mg (Arlevert, ARL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dimenhydrinate 50 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Betahistine dimesylate 12 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All medications
Number of subjects: 30
Study: 10905448

Group type: EXPERIMENTAL
Intervention: Pre-cued condition
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Post-cued condition
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: One-pair digits
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Three-pair digits
Number of subjects: 60
Study: 8642030

Group type: EXPERIMENTAL
Intervention: 30 mL of 0.5% bupivacaine and 1:200,000 epinephrine in saline solution after closure of the wound (Group 2)
Number of subjects: 82

Group type: COMPARATOR
Intervention: 30 mL of 0.5% bupivacaine and 1:200,000 epinephrine in saline solution before the incision (Group 1)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (30 mL of plain saline solution for both injections, Group 3)
Number of subjects: 82
Study: 1731547

Group type: COMPARATOR
Intervention: Propofol for induction and isoflurane-nitrous oxide for maintenance (control)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Propofol for induction and sevoflurane-nitrous oxide for maintenance
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sevoflurane-nitrous oxide for induction and maintenance
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sevoflurane-nitrous oxide
Number of subjects: 75

Group type: COMPARATOR
Intervention: Isoflurane-nitrous oxide
Number of subjects: 75
Study: 6487945

Group type: EXPERIMENTAL
Intervention: Submaximal heart rates assessed during workloads of 600 kpm
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Submaximal heart rates assessed during workloads of 750 kpm
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Submaximal heart rates assessed during workloads of 900 kpm
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Initial testing occasion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Second testing condition
Number of subjects: 24
Study: 29103656

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 200
Study: 27183253

Group type: EXPERIMENTAL
Intervention: ADAPT
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: HEART Pathway
Number of subjects: 141

Group type: COMPARATOR
Intervention: ADAPT and HEART Pathway
Number of subjects: 141
Study: 24343853

Group type: EXPERIMENTAL
Intervention: E-learning educational program
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study: 22771049

Group type: EXPERIMENTAL
Intervention: Buffered 2% lidocaine with epinephrine 1:100 000
Number of subjects: 54

Group type: COMPARATOR
Intervention: Unbuffered 2% lidocaine with epinephrine 1:100 000
Number of subjects: 54
Study: 20614235

Group type: EXPERIMENTAL
Intervention: EEG Biofeedback (Neurofeedback‐NFB) treatment, 20 sessions over 4 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Escitalopram treatment, 10 mg per day for 8 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: EEG Biofeedback (Neurofeedback‐NFB) treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Escitalopram treatment
Number of subjects: 36
Study: 17606494

Group type: EXPERIMENTAL
Intervention: B forceps biopsy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional biopsy (scalpel or punch)
Number of subjects: 84
Study: 16055454

Group type: EXPERIMENTAL
Intervention: Blastocyst-stage transfer (day 5)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Day-3 embryo transfer (control)
Number of subjects: 164
Study: 12361072

Group type: EXPERIMENTAL
Intervention: Bone SPECT with 99mTc‐hydroxymethylene‐diphosphonate
Number of subjects: 80
Study: 11414006

Group type: EXPERIMENTAL
Intervention: Participants who learned the RSIs by attending to their systematicity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incidental learning condition (unattended RSI systematicity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unattended RSIs learned when uniquely related to the tone sequence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ambiguous relation of RSIs
Number of subjects: 0
Study: 9278828

Group type: EXPERIMENTAL
Intervention: Uremic group (chronic renal failure)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (normal renal function)
Number of subjects: 60
Study: 8347179

Group type: EXPERIMENTAL
Intervention: Felbamate
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 3082344

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once a day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg three times a day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and atenolol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 28733257

Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle biopsy (FNB)
Number of subjects: 408

Group type: COMPARATOR
Intervention: EUS-guided fine-needle aspiration (FNA)
Number of subjects: 408
Study: 27982198

Group type: EXPERIMENTAL
Intervention: LT4/LT3 therapy (75/15 μg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: LT4 treatment (125 or 150 μg/day)
Number of subjects: 32
Study: 26585192

Group type: EXPERIMENTAL
Intervention: 2 g oral azithromycin
Number of subjects: 830

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 830
Study: 24385640

Group type: EXPERIMENTAL
Intervention: Cognitive training (10 initial sessions + 8 booster sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No cognitive training (attended none of the sessions)
Number of subjects: 0
Study: 20801255

Group type: EXPERIMENTAL
Intervention: Electric pulse frequency of electrocutaneous stimulation at 10 frequencies (0 to 120Hz)
Number of subjects: 26
Study: 18184245

Group type: EXPERIMENTAL
Intervention: Morphine 25 microg.kg(‐1) in 2% lidocaine hydrochloride with 1 : 1 00 000 epinephrine
Number of subjects: 42

Group type: COMPARATOR
Intervention: 2% lidocaine hydrochloride with 1 : 1 00 000 epinephrine (control group)
Number of subjects: 42
Study: 16521364

Group type: EXPERIMENTAL
Intervention: New typology of evidence for long-term conditions management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation tool for assessing research evidence
Number of subjects: 0
Study: 12796760

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 0
Study: 11092066

Group type: EXPERIMENTAL
Intervention: 21 mg/24-hour patch
Number of subjects: 244

Group type: COMPARATOR
Intervention: 15 mg/16-hour patch
Number of subjects: 244
Study: 8623952

Group type: EXPERIMENTAL
Intervention: Hospitak nasal cannula (HOS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Other nasal cannulae
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All nasal cannulae tested
Number of subjects: 20